Management of Hyperlipidemia: 2018 ACC/AHA Guideline Update

This Harvard Medical School Continuing Education video examines these key questions: How does lowering LDL-C fit into key strategies for secondary prevention and management of hyperlipidemia? What therapies have been identified to reduce LDL-C?
Dr. Pradeep Natarajan, MD, MMSC, the director of Preventive Cardiology at Massachusetts General Hospital, reviews the biology of blood lipids and proven strategies for improving cardiovascular health, including statins, diet, and medications.
00:00 | Introduction
00:29 | What are blood lipids and how do we measure them?
001:39 | Definition of secondary prevention and atherosclerosis
04:50 | Strategies for lowering cholesterol
09:05 | Summary
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Anna Handorf, MD, Research Fellow in Pediatrics, Massachusetts General Hospital and Bradley Petek, MD, Cardiovascular Performance Program, PGY-6, Massachusetts General Hospital.
References:
Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008;7(1):84-99. doi:10.1038/nrd2353
Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy [published correction appears in Lancet. 2017 Feb 11;389(10069):602]. Lancet. 2016;388(10059):2532-2561. doi:10.1016/S0140-6736(16)31357-5
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792
Miksenas H, Januzzi JL Jr, Natarajan P. Lipoprotein(a) and Cardiovascular Diseases. JAMA. 2021;326(4):352-353. doi:10.1001/jama.2021.3632
Notice: At this time, the content in this video is not accredited.